Effect of COX-2 inhibitor after TNBS-induced colitis in wistar rats

Effect of COX-2 inhibitor after TNBS-induced colitis in wistar rats

Author Ribeiro Paiotti, Ana Paula Autor UNIFESP Google Scholar
Miszputen, Sender Jankiel Autor UNIFESP Google Scholar
Oshima, Celina Tizuko Fujiyama Autor UNIFESP Google Scholar
Costa, Henrique de Oliveira Autor UNIFESP Google Scholar
Ribeiro, Daniel Araki Autor UNIFESP Google Scholar
Franco, Marcello Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Inflammatory bowel disease (IBD) is a common chronic gastrointestinal disorder characterized by alternating periods of remission and active intestinal inflammation. Some studies suggest that antiinflammatory drugs are a promising alternative for treatment of the disease. Thus, this study aimed to evaluate the effect of lumiracoxib, a selective-cyclooxygenase-2 (COX-2) inhibitor, on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis. Wistar rats (n = 25) were randomized into four groups, as follows: Group (1) Sham group: sham induced-colitis rats; Group (2) TNBS group: nontreated induced-colitis rats; Group (3) Lumiracoxib control group; and Group (4) Lumiracoxib-treated induced-colitis rats. Our results showed that rats from groups 2 and 4 presented similar histopathological damage and macroscopic injury in the distal colon as depicted by significant statistically differences (P < 0.01; P < 0.05) compared to the other two groups. Weak expression of COX-2 mRNA was detected in normal colon cells, while higher levels of COX-2 mRNA were detected in group 2 and group 4. Therapy with lumiracoxib reduced COX-2 expression by 20-30%, but it was still higher and statistically significant compared to data obtained from the lumiracoxib control group. Treatment with the selective COX-2 inhibitor lumiracoxib did not reduce inflammation-associated colonic injury in TNBS-induced experimental colitis. Thus, the use of COX-2 inhibitors for treating IBD should be considered with caution and warrants further experimental investigation to elucidate their applicability.
Keywords Inflammatory bowel disease
TNBS-colitis
Cyclooxygenase-2
Lumiracoxib
qRT-PCR
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Date 2009-08-01
Published in Journal of Molecular Histology. Dordrecht: Springer, v. 40, n. 4, p. 317-324, 2009.
ISSN 1567-2379 (Sherpa/Romeo, impact factor)
Publisher Springer
Extent 317-324
Origin http://dx.doi.org/10.1007/s10735-009-9243-0
Access rights Closed access
Type Article
Web of Science ID WOS:000272174800009
URI http://repositorio.unifesp.br/handle/11600/31706

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account